VLS Valneva SE

Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F

Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F

Saint-Herblain (France), March 25, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 24, 2025, of its 2024 Universal Registration Document (URD) with the French Financial Markets Authority (AMF) under the filing number D.25-0140 and its Form 20-F with the U.S. Securities and Exchange Commission (SEC).

Valneva’s 2024 Universal Registration Document – available in its entirety in French – includes the Company’s 2024 Annual Financial Report, the Company's Annual Management Report, the Board of Directors’ Corporate Governance Report and the Company’s Sustainability Statement. The Sustainability Statement is available in both English and French.

These documents are available on Valneva’s website () and will also be available on the AMF () and SEC () websites, respectively. Hard copies of these documents may be obtained from the Company, free of charge, upon request at the following address: 6 rue Alain Bombard, 44800 Saint-Herblain, France.

About Valneva SE

We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.

We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines, including the world’s first chikungunya vaccine, as well as certain third-party vaccines.

Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world’s most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against the Zika virus and other global public health threats. More information is available at .







Valneva Investor and Media Contacts

Laetitia Bachelot-Fontaine

VP, Global Communications and European Investor Relations

M +33 (0)6 4516 7099



















Joshua Drumm, Ph.D.

VP, Global Investor Relations

M 20













        
 

Attachment



EN
25/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

 PRESS RELEASE

Valneva Provides Update on Recommendation for Use of Its Chikungunya V...

Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities Saint Herblain (France), April 26, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that France’s national public health agency, the Haute Autorité de Santé (HAS), has updated its recommendation for use of Valneva’s single-dose chikungunya vaccine IXCHIQ® for the prevention of disease caused by the chikungunya virus (CHIKV) following reports of serious adverse events (SAEs) in elderly people with comorbidities during the ongoing vaccination campaign in ...

 PRESS RELEASE

Valneva fait un point sur la recommandation d’utilisation de son vacci...

Valneva fait un point sur la recommandation d’utilisation de son vaccin contre le chikungunya par les autorités françaises Saint Herblain (France), le 26 avril 2025 – (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que l’autorité publique de santé en France, la Haute Autorité de Santé (HAS), a mis à jour sa recommandation concernant l'utilisation du vaccin à dose unique de Valneva, IXCHIQ®, pour la prévention de la maladie causée par le virus du chikungunya (CHIKV) suite à une notification d'effets indésirables graves chez des personnes â...

 PRESS RELEASE

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vac...

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers Saint Herblain (France), April 18, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that during its regular meeting on April 16, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) updated its recommendation for use of Valneva’s single-dose chikungunya vaccine IXCHIQ® for the prevention of disease caused by the chikungunya virus (CHIKV). ACIP maintained its current recommendation for IXCHI...

 PRESS RELEASE

Valneva fait le point sur la recommandation de l'ACIP pour les voyageu...

Valneva fait le point sur la recommandation de l'ACIP pour les voyageurs américains concernant son vaccin IXCHIQ® contre le chikungunya Saint-Herblain (France), le 18 avril 2025 – (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que lors de sa réunion ordinaire du 16 avril 2025, le comité consultatif américain sur les pratiques d'immunisation (ACIP) des centres de contrôle et de prévention des maladies (CDC) a mis à jour sa recommandation concernant l'utilisation du vaccin à dose unique de Valneva, IXCHIQ®, pour la prévention de la maladie...

 PRESS RELEASE

Valneva to Participate in Multiple Events at the 25th World Vaccine Co...

Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ® Saint-Herblain (France), April 16, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its presence at the forthcoming 25th World Vaccine Congress, which will take place from April 21-24, 2025 at the Walter E. convention center in Washington, D.C. Under the leadership of the Company´s Chief Executive Officer, Thomas Lingelbach, a team of Valneva´s senior managers will participate in multiple events, including an impor...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch